Korea's Celltrion Eyes Eastern Bloc For Biosimilar Expansion

SEOUL - South Korean biopharmaceutical firm Celltrion posted record high profits in the third quarter, thanks to continued brisk shipment of its biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to countries in South America, the Middles East and Asia